Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06118372
Other study ID # HSR230248
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date August 1, 2024
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source University of Virginia
Contact Michael Mazzeffi, MD
Phone 434-924-9520
Email syy4wa@uvahealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of recombinant vWF in adult ECMO patients.


Description:

Coagulopathic bleeding is a common complication during ECMO. Multiple studies suggest that major bleeding occurs in 30-70% of adult ECMO patients, with higher bleeding rates in post-cardiotomy shock and veno-arterial (VA) ECMO patients. The pathophysiology of ECMO-induced coagulopathy is complex with multiple factors contributing, including loss of large VWF multimers, thrombocytopenia, increased tissue factor pathway inhibitor levels, and platelet surface glycoprotein (GP)1ba shedding. Adult ECMO patients almost universally develop acquired von Willebrand syndrome due to loss of large VWF multimers. In a study by Kalbhenn et al., acquired von Willebrand syndrome occurred within the first 6 hours of ECMO initiation in all patients (N=59) and returned to normal within 24 hours of ECMO decannulation. The loss of large VWF multimers that occurs in ECMO patients leads to poor platelet adhesion at an injury site and excess bleeding, which in some cases can become life-threatening. In a prior observational study, the investigators found that when adult ECMO patients with acquired von Willebrand syndrome were treated with plasma-derived vWF concentrate, it increased plasma ristocetin cofactor activity (RCo), increased the RCo-VWF antigen ratio, and improved clinical hemostasis. This preliminary data suggests that use of VWF may help to reduce bleeding in ECMO patients and is safe. Recombinant VWF has superior ultra-large multimer content, and thus it may be even better suited to treat acquired von Willebrand syndrome, which is represented by severe loss of large vWF multimers, similar to Type 2a von Willebrand disease. Further, recombinant VWF has a longer plasma half-life than plasma-derived VWF and may be safer because it contains no Factor VIII. Factor VIII activity is often supranormal during ECMO and overaccumulation of Factor VIII can increase thrombotic risk, particularly when there is blood stasis. In two prior in vitro studies, the investigators found that when recombinant VWF was added to ECMO patient blood samples, primary hemostasis/platelet adhesion returned towards normal. In a study that compared the addition of recombinant VWF to plasma-derived VWF, the investigators found that recombinant VWF improved primary hemostasis more, while having minimal impact on thrombin generation. These data suggest that recombinant VWF may be more effective in restoring primary hemostasis, and also may have a superior safety profile. The current study will investigate the safety and tolerability of recombinant VWF in adult ECMO patients with major bleeding.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 31, 2026
Est. primary completion date August 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult patients (18 years or greater) 2. On extracorporeal membrane oxygenation 3. Major bleeding defined by CTCAE class 3 or greater 4. Off systemic anticoagulation for at least 4 hours Exclusion Criteria: 1. Platelet count less than 40 x 109/L 2. International normalized ratio> 2.0 3. Fibrinogen less than 150 mg/dL 4. Current participation in another clinical trial (interventional) 5. Heparin induced thrombocytopenia (active) 6. Acute liver failure, as indicated by bilirubin >20 mg/dL or new onset hepatic encephalopathy 7. Patient or legally authorized representative unable to give informed consent 8. Allergy to recombinant von Willebrand Factor or any component of the product based on prior exposure 9. Of childbearing age and positive pregnancy test during the same hospital admission, a pregnancy test will be mandatory for all women of child-bearing age 10. Known congenital or acquired thrombophilia 11. History of deep venous thrombosis, pulmonary embolism, circuit thrombosis, disseminated intravascular coagulation (DIC), ischemic stroke, ST elevation myocardial infarction (STEMI), or arterial thrombosis in the last 3 months. 12. History of hypersensitivity to vWF concentrate 13. Known history of vWF antibodies

Study Design


Intervention

Drug:
Recombinant von Willebrand Factor
Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.

Locations

Country Name City State
United States UVA Hospital Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Country where clinical trial is conducted

United States, 

References & Publications (4)

Mazzeffi M, Bathula A, Tabatabai A, Menaker J, Kaczorowski D, Madathil R, Galvagno S, Pasrija C, Rector R, Tanaka K, Herr D. Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporea — View Citation

Mazzeffi M, Gonzalez-Almada A, Wargowsky R, Ting L, Moskowitz K, Hockstein M, Davison D, Levy JH, Tanaka KA. In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. J Cardioth — View Citation

Mazzeffi M, Hasan S, Abuelkasem E, Meyer M, Deatrick K, Taylor B, Kon Z, Herr D, Tanaka K. Von Willebrand Factor-GP1balpha Interactions in Venoarterial Extracorporeal Membrane Oxygenation Patients. J Cardiothorac Vasc Anesth. 2019 Aug;33(8):2125-2132. doi — View Citation

Mazzeffi M, Henderson R, Krause E, Rabin J, Madathil R, Chow J, Grazioli A, Meyer M, Wu Z, Tanaka K. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extraco — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serious Adverse Events Events that 1) cause death, 2) are life-threatening, 3) cause permanent damage, 4) required intervention to prevent harm, or 5) are otherwise serious and jeopardize the patient's safety. 30 days after treatment
Primary Area under the plasma concentration curve from zero to infinity (h × U/dL) Pharmacokinetic parameter 96 hours after treatment
Primary Plasma half-life (hours) Pharmacokinetic parameter 96 hours after treatment
Primary Mean residence time (hours) Pharmacokinetic parameter 96 hours after treatment
Primary Clearance (mL/kg per hour) Pharmacokinetic parameter 96 hours after treatment
Primary Volume at a steady state (dL/kg) Pharmacokinetic parameter 96 hours after treatment
Primary Maximum concentration (U/dL) Pharmacokinetic parameter 96 hours after treatment
Primary Time to maximum concentration (hours) Pharmacokinetic parameter 96 hours after treatment
Primary Incremental recovery ([U/dL]/[U VWF: RCo/kg] for VWF) Pharmacokinetic parameter 96 hours after treatment
Secondary Change in bleeding severity class The study's secondary endpoint will be any change in consensus definitions in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 bleeding class 24 hours after treatment with Vonvendi. 24 hours after treatment
Secondary Change in bleeding/drain output volume from existing surgical drains Change in total amount of bleeding/output from existing surgical drains will be a secondary study outcome. 24 hours after treatment
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT00772434 - Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument N/A
Completed NCT03871452 - The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding N/A
Recruiting NCT03095625 - Role of Thromboelastography in Septic Shock N/A
Recruiting NCT04600609 - Examining the Experiences of Children With Blood Disorders
Completed NCT02979158 - Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass N/A
Active, not recruiting NCT04912336 - Extracorporeal Life Support and Modification of Hemostasis
Terminated NCT05790109 - Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures. N/A
Not yet recruiting NCT05916469 - Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Recruiting NCT06250595 - European Rare Blood Disorders Platform (ENROL)
Completed NCT03355742 - XIENCE 28 Global Study N/A
Completed NCT03815175 - XIENCE 28 USA Study N/A
Completed NCT03444324 - Adjusted Fibrinogen Replacement Strategy Phase 3
Completed NCT02864875 - Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial Phase 4
Completed NCT04201860 - Blood Gas and Bleeding Disorders in Healthy Volunteers Exposed to Nitroglycerin and Nitrogen Compounds
Recruiting NCT04645199 - National Longitudinal Cohort of Hematological Diseases
Completed NCT05214300 - Screening for Bleeding Disorders in Children
Active, not recruiting NCT04188171 - Sclerotherapy With Polidocanol Foam In The Treatment Of Hemorrhoidal Disease In Patients With Bleeding Disorders Phase 2/Phase 3
Completed NCT06039904 - Protection of Knee Joints in Bleeding Disorder Patients N/A